RACING TO CURE

ALZHEIMER'S & PARKINSON'S

Biomarker Testing Is Step One!

Research supported by:

NIH
McGovern-Logo-1
ADDF-Logo-1

Why Early Detection?

To treat a disease, we must first know the condition exists. The earlier, the better.

Biomarker testing helps accelerate innovation for personalized treatment.

Lewy Body Dementia Test

Often, people with LBD encounter a difficult diagnostic journey. 

Our game-changing SYNTap Biomarker Test helps doctors make accurate LBD diagnoses.  

Parkinson’s Test

Our breakthrough SYNTap Biomarker Test helps doctors more accurately diagnose Parkinson’s disease (PD).

How It Works

We track the prion-protein biomarkers associated with Alzheimer’s, Parkinson’s, Lewy Body Dementia, and other brain diseases. 

Biomarker testing is the keystone for the cure.

A grandpa with his grandson, happy about Alzheimer's disease research

Why Early Detection

To treat a disease, we must first know the condition exists. The earlier, the better.

Biomarker testing helps accelerate innovation for personalized treatment.

Senior couple in the park

Lewy Body Dementia Test

Often, people with LBD encounter a difficult diagnostic journey. Our game-changing SYNTap Biomarker Test helps doctors make accurate LBD diagnoses.

parkinson's early trigger

Parkinson’s Test

Our breakthrough SYNTap Biomarker Test helps doctors more accurately diagnose Parkinson’s disease.

amprion science

How It Works

We track the prion-protein biomarkers associated with Alzheimer’s, Parkinson’s, Lewy Body Dementia, and other brain diseases.

Biomarker testing is the keystone for the cure.

Alzheimer’s & Parkinson’s - A Crushing Public Health Crisis

Play Video

Today, 5 million people in the US are diagnosed with Alzheimer’s, and 1 million with Parkinson’s. These numbers are expected to triple by 2050.

Despite billions spent on drug development, there’s no cure in sight.

Make an Impact! 

Be a Part of Big Brain Research

amprion logo quotes-gold

Every Alzheimer’s, Parkinson’s, and LBD patient is unique. To better care for each individual, we need personalized treatment.

Molecular diagnosis helps doctors gain insight into the person’s biomarker profile, advancing science to precision medicine.

Every Alzheimer’s, Parkinson’s, and LBD patient is unique. To better care for each individual, we need personalized treatment.

Molecular diagnosis helps doctors gain insight into the person’s biomarker profile, advancing science to precision medicine.

Amprion Mission

Claudio Soto, CoFounder & CSO

amprion logo quote solid blue
Science is powerful. I want to change the world through science.

Claudio Soto, CoFounder & CSO

amprion logo quote solid blue
Science is powerful. I want to change the world through science.

Scroll to Top
Share on facebook
Share on twitter
Share on linkedin
Amprion Icon
Make Every Minute Count. Join the Fight!